gms | German Medical Science

21st Annual Meeting of the German Retina Society and 8th Symposium of the International Society of Ocular Trauma (ISOT)

German Retina Society
International Society of Ocular Trauma

19.06. - 22.06.2008, Würzburg

Bevacizumab versus triamcinolone for treatment of diabetic macular edema in a pair-matched analysis

Meeting Abstract

  • Rainer Guthoff - Würzburg/Germany
  • K. Hennemann - Würzburg/Germany
  • W. Goebel - Würzburg/Germany
  • W.F. Schrader - Würzburg/Germany

Retinologische Gesellschaft. International Society of Ocular Trauma. 21. Jahrestagung der Retinologischen Gesellschaft gemeinsam mit dem 8. Symposium der International Society of Ocular Trauma. Würzburg, 19.-22.06.2008. Düsseldorf: German Medical Science GMS Publishing House; 2008. DocISOTRG2008V140

The electronic version of this article is the complete one and can be found online at:

Published: June 18, 2008

© 2008 Guthoff et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Background: To retrospectively analyze the outcome of patients with diabetic macular edema (ME) treated by bevacizumab vs. triamcinolone.

Methods: 14 patients treated with bevacizumab for argon laser-refractory diabetic ME were matched pairwise with 5 TA treated patients in regard to initially comparable VA and central retinal thickness (CRT). VA and CRT, measured by OCT, at first and last presentation were evaluated. Previously vitrectomized eyes were not included.

Results: In the BVO group, mean initial VA (LogMAR) of bevacizumab patients (mean age 70±13 years) and TA patients (mean age 65±9 years) was 0.2±0.1 and 0.19±0.09, respectively. Initial CRT of bevacizumab patients and TA patients was 470±181 µm and 469±169 µm, respectively. Final VA of bevacizumab patients after 1.3 injection was 0.17±0.05, mean 0,2, at the end of a mean follow up of 8±3.8 months. Final VA of TA patients after a mean of 1.1 injections was 0.21±0.1, median 0,2, at the end of a mean follow up of 9.5±5.3 months. CRT decreased by 119±212µm, median 92µm, after bevacizumab und by 103±171µm, median 92µm, after TA.

Conclusions: This pair-machted analysis showed no significant long-term effect of both bevacizumab and TA on chronic diabetic macular edema after a single up to 3 injections.